Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - PLURISTEM THERAPEUTICS INC | exhibit_10-1.htm |
| 10-Q - 10-Q - PLURISTEM THERAPEUTICS INC | zk1719875.htm |
| EX-32.3 - EXHIBIT 32.3 - PLURISTEM THERAPEUTICS INC | exhibit_32-3.htm |
| EX-32.2 - EXHIBIT 32.2 - PLURISTEM THERAPEUTICS INC | exhibit_32-2.htm |
| EX-31.3 - EXHIBIT 31.3 - PLURISTEM THERAPEUTICS INC | exhibit_31-3.htm |
| EX-31.2 - EXHIBIT 31.2 - PLURISTEM THERAPEUTICS INC | exhibit_31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - PLURISTEM THERAPEUTICS INC | exhibit_31-1.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
18 U.S.C. SECTION 1350
In connection with the Quarterly Report (the “Report”) of Pluristem Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, Zami Aberman, Co-Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
|
1.
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
Date: May 8, 2017
|
By: /s/ Zami Aberman
—————————————— Zami Aberman Co-Chief Executive Officer |